In the European Union,<unk>  is indicated for the treatment of adults with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.
Regdanvimab
Atoltivimab
Odesivimab
Nirsevimab
Obiltoxaximab
Sotrovimab
Lirentelimab
Ansuvimab